Received Feb 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | CX4HL | — |
A twelve year old patient received a first dose of BOOSTRIX on August eight twenty-twenty four and a second dose today; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 12-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number CX4HL, expiry date 09-NOV-2026) for prophylaxis. Previously administered products included Boostrix (received 1st dose on 08-AUG-2024). On 11-FEB-2025, the patient received the 2nd dose of Boostrix. On 11-FEB-2025, an unknown time after receiving Boostrix, the patient experienced extra dose administered (Verbatim: A twelve year old patient received a first dose of BOOSTRIX on August eight twenty-twenty four and a second dose today). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-FEB-2025 The reporter gave a Boostrix vaccine that was not needed. A patient received a first dose of Boostrix and received second dose on the day of reporting which led to extra dose administered. Licensed practice nurse inquired about any advice on this situation. Vaccination date, vaccine detail and patient demographics were obtained in this call. No further information was obtained in this call. The vaccine administration facility was the same as primary reporter.